Perceptive Advisors’s Urovant Sciences Ltd. UROV Stock Holding History

Perceptive Advisors’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,116,831	Closed	-$50.3M	–	172
2020 Q4	$50.3M	Buy	3,116,831 +750,000	+32%	+$9.3M	0.54%	46
2020 Q3	$22.1M	Hold	2,366,831	–	–	0.32%	64
2020 Q2	$23.3M	Hold	2,366,831	–	–	0.38%	55
2020 Q1	$21.8M	Sell	2,366,831 -40,100	-2%	-$482K	0.57%	41
2019 Q4	$37.3M	Buy	2,406,931 +160,384	+7%	+$1.74M	0.74%	34
2019 Q3	$21.3M	Buy	2,246,547 +371,121	+20%	+$3.22M	0.57%	44
2019 Q2	$14.8M	Buy	1,875,426 +1,010,067	+117%	+$8.29M	0.34%	55
2019 Q1	$8.7M	Buy	865,359 +240,000	+38%	+$2.46M	0.25%	62
2018 Q4	$3.92M	Buy	625,359 +162,700	+35%	+$1.48M	0.15%	66
2018 Q3	$5.55M	Buy	+462,659	New	+$5.47M	0.15%	69

Perceptive Advisors's UROV Position: Q1 2021 in Review

Perceptive Advisors sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 3,116,831 shares — an estimated $50.3M sold.

Perceptive Advisors first reported a position in UROV in Q3 2018 and held it in 10 quarters. The position peaked at $50.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Perceptive Advisors reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Perceptive Advisors sold 3,116,831 Urovant Sciences Ltd. shares in Q1 2021, an estimated $50.3M.
Perceptive Advisors first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 10 quarters.
Perceptive Advisors's Urovant Sciences Ltd. position peaked at $50.3M in Q4 2020.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.